

Sent: Monday, 29 November 2021 12:31 PM

To: VOICEMAIL, OGTR

<OGTR.Voicemail@health.gov.au**>**

Subject: Risk assessment for covid gene therapies

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear Dr Raj Bhula

I am writing to seek updates on risk assessments of Covid gene therapies available in Australia . Can you please advise if a risk assessment from your office exists for Pfizer/Comirnaty and Moderna?

I note that the last updated risk assessment for genetically modified gene therapy DIR180 Astra Zeneca was completed Feb 2021, prior to the mass rollout in Australia .

Real time data collected over the last 11 months which we know has been under reported due to constraints from healthcare, clearly indicates that reoccurring adverse reactions are of concern which were not tabled as a risk at the time of assessment.

As your role of regulator which is to protect the health and safety of people, and to protect the environment, by identifying risk posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with genetically modified organisms (GMOs), I ask that Australians be given an updated risk assessment plan which deals with new evidence of personal risks to individuals taking these genetically modified genes in the Astra Zeneca vaccines.

The last available risk assessment below is from feb 2021. https://www.ogtr.gov.au/sites/default/files/2021-06/dir180-full_risk_assessment_and_risk_management_plan.pdf

I look forward to the latest information being made publicly available for all current Covid gene therapies .

Regards